Endo International PLC (NASDAQ:ENDP) Short Interest Down 11.0% in June

Endo International PLC (NASDAQ:ENDP) was the target of a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 20,084,394 shares, a decrease of 11.0% from the June 15th total of 22,575,855 shares. Based on an average daily volume of 5,194,844 shares, the days-to-cover ratio is presently 3.9 days. Approximately 10.1% of the shares of the stock are sold short.

Shares of Endo International PLC (ENDP) traded up 0.40% on Monday, hitting $7.62. The stock had a trading volume of 13,398,642 shares. The firm’s market cap is $1.70 billion. The firm’s 50-day moving average price is $10.93 and its 200 day moving average price is $11.55. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $24.93.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same period last year, the company posted $0.86 earnings per share. The firm’s revenue was down 4.9% compared to the same quarter last year. On average, equities research analysts predict that Endo International PLC will post $3.52 EPS for the current year.

In other Endo International PLC news, COO Terrance J. Coughlin purchased 20,000 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the purchase, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. OppenheimerFunds Inc. raised its stake in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after buying an additional 1,857,678 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. First Quadrant L P CA purchased a new stake in shares of Endo International PLC during the first quarter valued at $24,556,000. Norges Bank purchased a new stake in shares of Endo International PLC during the fourth quarter valued at $26,929,000. Finally, Teachers Advisors LLC raised its stake in shares of Endo International PLC by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after buying an additional 15,928 shares in the last quarter. 92.27% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have recently commented on the company. Canaccord Genuity set a $12.00 target price on Endo International PLC and gave the company a “hold” rating in a research report on Thursday, June 8th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a report on Thursday, June 8th. Stifel Nicolaus lowered Endo International PLC from a “buy” rating to a “hold” rating and decreased their price target for the company from $22.00 to $15.00 in a report on Friday, June 9th. ValuEngine lowered Endo International PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Mizuho restated a “buy” rating and set a $19.00 price target (up previously from $18.00) on shares of Endo International PLC in a report on Thursday, May 25th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have issued a buy rating to the company. Endo International PLC currently has an average rating of “Hold” and an average target price of $14.86.

TRADEMARK VIOLATION WARNING: This report was first posted by [[site]] and is the property of of [[site]]. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at [[permalink]].

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.